Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| CONSORT Reporting Checklist× | Cochrane RoB 2.0× | |
|---|---|---|
| Valdkond | Uurimismetodoloogia | Uurimismetodoloogia |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 2010 (original 1996) | 2019 |
| Looja≠ | Schulz et al. (CONSORT Group) | Jonathan Sterne, Julian Higgins (Cochrane Collaboration) |
| Tüüp≠ | Trial author reporting checklist | Clinician-rated / Research team assessment |
| Algallikas≠ | Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. The Lancet, 375(9721), 1657–1668. DOI ↗ | Sterne, J. A., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., ... & Higgins, J. P. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. DOI ↗ |
| Rööpnimetused | CONSORT, CONSORT 2010 | RoB 2.0, RoB 2 |
| Seotud | 4 | 4 |
| Kokkuvõte≠ | The CONSORT (Consolidated Standards of Reporting Trials) Statement is a 25-item evidence-based checklist and flow diagram developed to standardize reporting of parallel-group randomized controlled trials. First published in 1996 and updated in 2010 (CONSORT 2010), it is endorsed by over 600 journals including The Lancet, JAMA, and BMJ, and is mandatory or strongly recommended for RCT manuscript submission across clinical research. | RoB 2 is the Cochrane Collaboration's updated methodology for assessing the risk of bias in randomized controlled trials (RCTs). Published in 2019, it replaced the original Cochrane RoB tool with a more structured, transparent approach using signalling questions and domain-based judgments to evaluate five critical sources of bias. |
| ScholarGateAndmestik ↗ |
|
|